Aprea Therapeutics Inc

Aprea Therapeutics reported second-quarter 2026 financial results and business updates, highlighting accelerating enrollment in the Phase 1 ACESOT-1051 trial of its oral WEE1 inhibitor APR-1051. The company expanded active clinical sites from three to ten and expects enrollment to reach 6 to 10 patients per month by Q4 2026. Aprea plans to advance APR-1051 as a single agent in uterine serous carcinoma and Cyclin E-overexpressing platinum-resistant ovarian cancer, while also evaluating combinations with standard-of-care therapies in HPV-positive head and neck cancer and colorectal cancer. Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity, including partial responses and disease stabilization, with a manageable tolerability profile. For the second quarter ended June 30, 2026, Aprea reported an operating loss of $4.0 million, compared with $3.4 million in the prior-year quarter, and a net loss of $3.6 million, or $0.07 per basic share, compared with a net loss of $3.2 million, or $0.53 per basic share, in Q2 2025. The company held $41.2 million in cash and cash equivalents as of June 30, 2026, and expects its cash to support currently projected operating expenses and capital requirements into Q1 2028.